English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objective: To evaluate all the known factors that may play a role in predicting response to Neoadjuvantchemotherapy in breast cancer and to see impact of response on five years’ disease free survival (DFS) andOverallsurvival (OS).Material and Method: Data of 156 patients was reviewed retrospectively from January 2012 to December2012 at Shaukat Khanum Memorial Cancer Hospital and Research Centre Lahore, Pakistan. All receivedneoadjuvant chemotherapy (NAC) and had no distant metastasis. The response was measured in term ofpercentage reduction from 1st radiological size on presentation to final size on histopathology (of resectedspecimen). Four groups were identified, complete responder (CR) (100% reduction), Responders (R) (&gt;50%reduction), Partial responder (PR) (&lt;50% reduction) and Non-responder (NR). Relationship of predictivefactors with each response group was observed. Five year survival was noted for each response group.Result: Median age of patients was 45 years (25-64 years). 67% of patients underwent breast conservationsurgery, while the rest underwent mastectomy. Mortality for whole group was 22%, and recurrence wasshown in 34% (Majority i.e. 26% were distant, while contralateral were 3%). Out of 156 patients, 25% ofpatients were CR, 13% were NR, 23% were PR and 37% were R. Progesterone receptor negative and GradeIII tumors showed more complete responses. The Rest of the receptor types, including triple negative, initialT and N stage and other clinical factors showed no impact on chemo-response. Survival was significantlypoor in NR group (45% OS, 40% DFS), while rest of three groups had comparable survival outcome, withCR group having best survival outcome (86% OS, 80% DFS).Conclusion: Most of factors studied did not show impact on achieving good chemo response, however goodchemo response did show better survival.

clinical oncology and research

Predictive Factors Involved in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer and Impact of Response on 5 Years Disease Free Survival and Overall Survival